跳至主要内容
临床试验/NCT01185405
NCT01185405撤回不适用

Prediction and Adjustment of Voriconazole Plasma Level in Critically Ill Patients

Asan Medical Center2 个研究点 分布在 1 个国家开始时间: 2010年8月最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
试验地点
2
主要终点
Appropriateness of voriconazole trough level

研究概览

简要总结

Voriconazole, a newer triazole-derivative, has become the drug of choice for many invasive fungal infections, including invasive Aspergillosis. Recently, therapeutic drug monitoring of voriconazole has been issued because of wide variations and unpredictability of voriconazole blood concentration. The objective of this study is 1) to characterize the pharmacokinetics of voriconazole in ICU patients on voriconazole prophylaxis or treatment, and 2) to develop and evaluate the prediction and adjustment models for voriconazole plasma levels.

详细描述

Patients will be randomly assigned into 2 groups: conventional adjustment group (CA group) and early adjustment group (EA group). Voriconazole plasma levels will be measured on day 1 (both peak and trough levels), day 3, day 5, day 10, and day 14 (all trough levels). For CA group patients, voriconazole dosage will be adjusted according to the trough levels of day 5 (steady-state level). Predefined dose adjustment protocol will be used (< 1 µg/ml: 50% increase, 1~5.5 µg/ml: no change, > 5.5 µg/ml: 50% decrease). For EA group patients, voriconazole dosage will be adjusted according to the each measurements of voriconazole levels from day 1. Adjusted dosage will be calculated using the NONMEN software. The target range of trough level is between 1.0 µg/ml and 5.5 µg/ml. The appropriateness of voriconazole level (day 5, day 10, and day 14), mortality, ICU stay, and the frequency of voriconazole-related adverse events will be compared. CYP2C19 polymorphism will be analyzed for all patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients who received voriconazole

排除标准

  • Patients allergic to azole(s)

结局指标

主要结局

Appropriateness of voriconazole trough level

时间窗: Day 3, day 5, day 10, and day 14

次要结局

  • Mortality(2 week, 4 week, 8 week, 12 week, and 24 week)
  • Voriconazole-related adverse event(1 week, 2 week)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Sang-Ho Choi

Doctor

Asan Medical Center

研究点 (2)

Loading locations...

相似试验